Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,268 GBX | +0.16% | +2.21% | +6.30% |
Apr. 23 | AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder | MT |
Apr. 23 | ASTRAZENECA : JP Morgan reaffirms its Buy rating | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.30% | 215B | |
+27.92% | 659B | |
+27.68% | 557B | |
-4.59% | 359B | |
+16.38% | 322B | |
+9.39% | 297B | |
+4.80% | 210B | |
-6.05% | 200B | |
-8.58% | 149B | |
-4.99% | 146B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Heart Failure Drug Wins EU Nod for Expanded Use in Full Ejection Fraction Range